Purpose: We report contemporary outcomes of salvage cryoablation at a large number of centers which have participated in the COLD (Cryo On-Line Data) Registry.
Materials And Methods: A secure online database was developed to collect data for patients undergoing prostate cryoablation. Kaplan-Meier analysis was performed with biochemical failure defined using the American Society of Therapeutic Radiology and Oncology, and the Phoenix definitions.
Results: Data from 279 patients who had undergone salvage cryoablation were entered. Average patient age was 70.0 +/- 7.1 years. Pretreatment prostate specific antigen was 7.6 +/- 8.2 ng/ml and Gleason score was 7.5 +/- 1.1 (median 7). Patients were followed for 21.6 +/- 24.9 months and 47 were followed longer than 5 years. The 5-year actuarial biochemical disease-free rates were 58.9% +/- 5.7% (American Society of Therapeutic Radiology and Oncology) and 54.5% +/- 4.9% (Phoenix). As predicted based on the preservation of some prostatic tissue, 83% +/- 3.5% of patients had a detectable prostate specific antigen 0.2 ng/ml or greater at 5 years. Positive biopsies were observed in 15 of the 46 patients (32.6%) who underwent prostate biopsy after salvage cryotherapy. The incontinence rate (requiring pad use) was 4.4%. The rectal fistula rate was 1.2% and 3.2% of patients underwent transurethral prostate resection to remove sloughed tissue.
Conclusions: Biochemical and local control rates support the use of salvage cryoablation for localized recurrence following failed radiation therapy. Efforts to continue to minimize these complications and to improve disease control in patients with persistent cancer following definitive radiotherapy should continue.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.juro.2008.04.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In-field prostate cancer recurrence following radical prostatectomy and salvage radiation.
BJU Int
November 2024
Department of Urology, Mayo Clinic, Phoenix, AZ, USA.
Objective: To define the natural history, patterns of recurrence and treatment modalities for local prostate cancer (PCa) recurrence following radical prostatectomy (RP) and radiation therapy (RT), and to investigate factors that could predict metastasis-free survival (MFS) in this unique patient population.
Methods: We queried a prospectively maintained PCa registry to identify men developing in-field recurrence (IFR) following RP and RT from 2008 to 2021 at a single institution. IFR was defined as biopsy-proven recurrent PCa or the presence of persistent positron emission tomography-avid lesions in the prior radiation field without evidence of metastasis.
Five-year Oncologic Outcomes Following Primary Partial Gland Cryo-ablation Prospective Cohort Study of Men With Intermediate-risk Prostate Cancer.
Urology
October 2024
Department of Urology, NYU Grossman School of Medicine, New York, NY. Electronic address:
Objective: To assess 5-year oncologic outcomes following primary partial gland cryo-ablation (PPGCA) in intermediate-risk prostate cancer.
Methods: Of 476 men undergoing PPGCA enrolled in our prospective oncologic and functional outcomes study, 313 had magnetic resonance imaging (MRI) concordant intermediate-risk prostate cancer with no out-of-field Gleason grade group ≥2, gross extracapsular extension, or extreme apical disease on pre-treatment multi-parametric MRI. Prostatic-specific antigen was monitored every 6 months, and multi-parametric MRI at 6 to 12, 24, 42, and 60 months.
Propensity score-matched analysis comparing robot-assisted partial nephrectomy and image-guided percutaneous cryoablation for cT1 renal cell carcinoma.
Urol Oncol
December 2024
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Article Synopsis
- - This study compared the clinical outcomes of robot-assisted partial nephrectomy (RAPN) and image-guided percutaneous cryoablation (IG-PCA) in patients with clinical T1 renal cell carcinoma over a period from 2012 to 2021, analyzing data from 679 patients.
- - After matching for baseline characteristics, 108 patients from each treatment group showed that while RAPN had no local recurrences, IG-PCA had three cases of tumor progression, which were successfully treated with additional thermal ablations.
- - Overall, both treatments had similar long-term survival rates, complication rates, and renal function preservation, indicating that IG-PCA can provide oncological outcomes that are comparable to RAPN.
The Role of Whole-Gland and Focal Cryotherapy in Recurrent Prostate Cancer.
Cancers (Basel)
September 2024
Department of Urology, George Washington University School of Medicine, 2300 I St NW, Washington, DC 20052, USA.
Article Synopsis
- * Salvage prostatectomy is effective but can lead to significant complications and poor functional results, prompting interest in salvage cryotherapy as a safer alternative for localized recurrence.
- * This review focuses on the effectiveness of whole-gland and focal salvage cryotherapy, the importance of advanced imaging techniques like multiparametric MRI and PSMA-targeted PET, and how cryotherapy compares to other treatments like high-intensity focused ultrasound (HIFU).
Cryotherapy versus radical prostatectomy as a salvage treatment for radio-recurrent prostate cancer.
World J Urol
September 2024
Department of Urology, Institut Mutualiste Montsouris, 42 boulevard Jourdan, Paris, 75014, France.
Introduction: The aim of this study is to compare outcomes of SRP (salvage radical prostatectomy) with SCAP (salvage cryoablation of the prostate) in local radio-recurrent PCa (prostate cancer) patients.
Materials And Methods: A retrospective analysis of a multicentric European Society of Uro-technology (ESUT) database was performed. Data on patients with local recurrent PCa after radiotherapy who underwent salvage treatment were collected.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!